E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10023476 |
E.1.2 | Term | Knee osteoarthritis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of duloxetine 60 mg QD compared with placebo on the reduction of pain severity as measured by the Brief Pain Inventory (BPI) – Modified Short Form 24-hour average pain rating in patients with OA knee pain during a 13-week, double-blind, treatment period. |
|
E.2.2 | Secondary objectives of the trial |
Secondary Gatekeeper Objectives •To evaluate duloxetine 60 mg QD versus placebo on patients’ perceived improvement during the 13-week treatment period as measured byPGI – Improvement • To evaluate duloxetine 60 mg QD versus placebo on the change in patients’ functioning during the 13-week treatment period as measured by the WOMAC physical function subscale Secondary Objectives • To assess the efficacy of duloxetine 60 mg QD versus placebo during the 13-week treatment period as measured by: CGI-Severity, WOMAC, BPI, Response to treatment, Sustained response to treatment, b-POMS • To assess the impact of treatment on patient-reported health outcomes, as measured by: SF-36, EQ-5D • To evaluate the safety of duloxetine 60 mg QD: discontinuation rates of patients, incidence of TEAEs, AEs and SAEs, changes in laboratory test values, changes in vital signs and weight,C–SSRS |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
[1] Are male or female outpatients at least 40 years of age. [2] Female patients: women of child-bearing potential who test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use a reliable method of birth control during the study and for 1 month following the last dose of study drug; OR women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. [3] Meet the American College of Rheumatology (ACR) clinical and radiographic criteria for the diagnosis of OA of the knee [4] Have OA knee pain for ≥14 days of each month for 3 months prior to study entry. [5] Have a rating of greater than or equal to 4 on the BPI average pain item (Question 3 of the BPI modified short form) at both Visit 1 and Visit 2. [6] Have an education level and a degree of understanding such that the patient can communicate intelligibly with the site study personnel. [7] Are judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol. [8] Have agreed to maintain the same activity level throughout the course of the study. Continuation of long-term, regular, non-pharmacological treatments such as physical therapy or relaxation therapy is allowed. |
|
E.4 | Principal exclusion criteria |
[9] Are investigator site personnel directly affiliated with this study and/or their immediate families [10] Are employed by Lilly [11] Are currently enrolled in, or discontinued within the last 30 days from, a clinical study involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study [12] Have previously completed or withdrawn from this study or any other study investigating duloxetine [13] Have had any previous exposure to duloxetine [14] Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder [15] Have MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, as assessed by the Mini International Neuropsychiatric Interview or diagnosed within the past year [16] Have a history of substance abuse or dependence within the past year [17] Are taking any excluded medications that cannot be discontinued at Visit 1 [18] Have current or pending disability compensation or litigation issues that may compromise response to treatment, in the opinion of the investigator [19] Have had treatment with a MAOI within 14 days of randomization or the potential need to use an MAOI during the study or within 5 days of discontinuation of study drug. [20] Have a positive urine drug screen for any substance of abuse or excluded medication. [21] Are pregnant or breast-feeding [22] Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study [23] Have a history of recurrent seizures other than febrile seizures [24] Are judged by the investigator to be at suicidal risk [25] Have uncontrolled narrow-angle glaucoma [26] Have acute liver injury or severe cirrhosis [27] Have known hypersensitivity to duloxetine or any of the inactive ingredients or patients with frequent or severe allergic reactions to multiple medications [28] Have frequent falls that could result in hospitalization or could compromise response to treatment [29] Have a confounding painful condition that may interfere with assessment of the index joint, that is, knee. [30] Have a diagnosis of inflammatory arthritis or an autoimmune disorder [31] Have received intrarticular hyaluronate or steroids, joint lavage, or other invasive therapies to the knee in the past 3 months [32] Have had knee arthroscopy of the index knee within the past year or joint replacement of the index knee at anytime [33] Have surgery planned during the study for the index joint [34] Have had a prior synovial fluid analysis showing a white blood cell (WBC) ≥2000 mm3 that is indicative of a diagnosis other than OA. [35] Are non-ambulatory or require the use of crutches or a walker. [36] Have a BMI over 40. [37] Use of acupuncture, chiropractic maneuvers, TENS [38] Patients who are anticipated by the investigator to require use of analgesic agents including but not limited to NSAIDs, acetaminophen/paracetamol, and opioids, or other excluded medication for the duration of the study. [39] Are unwilling or unable to comply with the data collection method used to record their patient rated outcome data. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy measure for this study is the BPI “24-hour average pain” item (Question 3) of the BPI – Modified Short Form. The BPI is a self-reported scale that measures the severity of pain and the interference of pain on function. For the BPI 24-hour average pain item, the ratings range from 0 (no pain) to 10 (pain as severe as you can imagine). Data will be collected at scheduled office visits. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Impact on patient-reported health outcomes |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |